Recruiting

Tissue Sodium Quantification in Patients With Primary Aldosteronism: See Sodium to Treat

The study aims to provide quantitative facts on the pathophysiological changes in tissue Na+ content during Na+/K+ redistribution disorders in patients with PA in response to standard therapy. The investigators hypothesize that patients with primary aldosteronism have excessive Na+ storage in the muscle, which can now be quantified non-invasively using 23NaMRI. In analogy to the role of HbA1c as a metabolic long-term marker in diabetes, the quantifiable changes in muscle Na+ content may deliver the data evidence…

ClinicalTrials.gov IDNCT06569589

PhaseNot Applicable

Enrollment80

SponsorJens Titze

Age21 Years – 70 Years

SexALL

I'm interested View official listing

Conditions studied

Hypertension, Primary Aldosteronism, Hypokalemia

About this study

Interventions

Diagnostic Test: 23NaMRI Scan — 23NaMRI, a non-invasive detection and quantification of hidden tissue Na+ stores in humans.
Dietary Supplement: Potassium Chloride (KCl) — K+ supplementation intervention is given participants as part of their standard care. In this trial the K+ supplementation dosage is standardized and adjusted based on blood K+ level

Primary outcomes

Patients with primary aldosteronism have a 10-20% higher muscle Na+ content compared to healthy controls (Baseline)

Eligibility information

Inclusion Criteria: 1. Age 21-70 years, with arterial hypertension or suspected to have primary aldosteronism based on Endocrine Society Guidelines. 2. Male and female patients older than 21 years. 3. Willingness to participate and ability to provide informed consent. Exclusion Criteria: 1. Patients with exclusion criteria for the MRI, such as: * implanted devices (surgical clips, heart pacemakers or defibrillators, cochlear implants) * iron-based tattoos * any other pieces of metal or devices that are not MR-Safe anywhere in the body * patients who exhibit noticeable anxiety and/or claustrophobia into the MRI scanner * pregnancy 2. Diagnosis of heart failure NYHA classes III and IV 3. Impaired renal function with eGFR\<30 ml/min or proteinuria \> 1 g/24h 4. Liver disease with cirrhosis (Child-Pugh class C) or hypoalbuminemia 5. Muscular dystrophies 6. Patients with active cancer or severe comorbid conditions likely to compromise survival or study participation 7. Unwillingness or other inability to cooperate

Study locations

Singapore General Hospital, Singapore, 169608 Singapore
Duke NUS Medical School, Singapore, 169857 Singapore
Changi General Hospital, Singapore, 529889 Singapore
Sengkang General Hospital, Singapore, 544886 Singapore

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-27.